在2019冠状病毒病试验中协调异质性终点而不丢失信息
本文针对COVID-19随机对照试验中终点异质性问题,提出基于住院、机械通气、死亡和出院四种状态的多状态模型,并建议用堆叠概率图描述时间动态治疗效果。该模型与WHO推荐的序数终点及COMET核心结局集一致。文中通过注册试验综述和真实/重建数据展示堆叠概率图能详细呈现治疗对住院过程的影响,有助于在试验内和试验间协调多个终点及不同随访时长。主要分析仍应聚焦于具有替代潜力的早期终点,多状态模型提供补充描述信息。
要点
- 多状态模型基于住院、机械通气、死亡和出院四种状态,与WHO序数终点及COMET核心结局集一致。
- 多数COVID-19试验收集机械通气、住院和死亡信息,支持该状态选择。
- 堆叠概率图可详细展示治疗对患者住院过程的影响,协调多个终点和不同随访时长。
- 所有进行中的临床试验应在统计分析计划中纳入堆叠概率图作为描述性分析。
- 主要分析应聚焦于具有适当替代能力的早期终点,多状态模型提供补充描述信息。
适用人群与场景
- 感染COVID-19并参与随机对照试验的个体
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究设计为方法学开发与注册试验简要综述,基于多状态模型(住院、机械通气、死亡、出院)提出统计建议;多数COVID-19试验收集机械通气、住院和死亡信息;使用重建和真实数据展示堆叠概率图可详细理解治疗对住院过程的影响,有助于协调试验内和试验间的多个终点及不同随访时长。
证据类型、等级与局限
- 证据类型为方法学文章(含注册试验简要综述);原文未给出证据等级或推荐强度;局限包括未提及具体样本量、中心数及统计效能,方法学建议需进一步验证。
对床旁实践的改变
- 建议所有进行中的COVID-19临床试验在统计分析计划中纳入堆叠概率图作为描述性分析,以协调异质性终点并保留时间动态信息;主要分析应聚焦于具有适当替代能力的早期终点;不适用于非COVID-19试验或未收集住院、机械通气、死亡、出院信息的试验;常见陷阱为将堆叠概率图误用作主要推断分析而非描述性补充。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Many trials investigate potential effects of treatments for coronavirus disease 2019. To provide sufficient information for all involveddecision-makers (clinicians, public health authorities, and drug regulatory agencies), a multiplicity of endpoints must be considered. The objectives are to provide hands-on statistical guidelines for harmonizing heterogeneous endpoints in coronavirus disease 2019 clinical trials.
DESIGN: Randomized controlled trials for patients infected with coronavirus disease 2019.
SETTING: General methods that apply to any randomized controlled trial for patients infected with coronavirus disease 2019.
PATIENTS: Coronavirus disease 2019 positive individuals.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We develop a multistate model that is based on hospitalization, mechanical ventilation, death, and discharge. These events are both categories of the ordinal endpoint recommended by the World Health Organization and also within the core outcome set of the Core Outcome Measures in Effectiveness Trials initiative for coronavirus disease 2019 trials. To support our choice of states in the multistate model, we also perform a brief review of registered coronavirus disease 2019 clinical trials. Based on the multistate model, we give recommendation for compact, informative illustration of time-dynamic treatment effects and explorative statistical analysis. A majority of coronavirus disease 2019 clinical trials collect information on mechanical ventilation, hospitalization, and death. Using reconstructed and real data of coronavirus disease 2019 trials, we show how a stacked probability plot provides a detailed understanding of treatment effects on the patients' course of hospital stay. It contributes to harmonizing multiple endpoints and differing lengths of follow-up both within and between trials.
CONCLUSIONS: All ongoing clinical trials should include a stacked probability plot in their statistical analysis plan as descriptive analysis. While primary analysis should be on an early endpoint with appropriate capability to be a surrogate (parameter), our multistate model provides additional detailed descriptive information and links results within and between coronavirus disease 2019 trials.
参考来源
- von Cube M, Grodd M, Wolkewitz M, et al. Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information. Crit Care Med. 2021. PMID: 33148952. doi:10.1097/CCM.0000000000004741
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。